Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018

      This image opens in the lightbox

      News provided by

      Alkermes plc

      14 Feb, 2018, 12:00 GMT

      Share this article

      Share this article


      —    Record Revenues of $903.4 Million, GAAP Loss Per Share of $1.03 and Non-GAAP Diluted Earnings Per Share of $0.17 Reported for 2017 —

      —    2017 Net Sales of Proprietary Products Grew by 42% Year-Over-Year —

      —    2018 Net Sales of Proprietary Products Expected to Grow by Approximately 28%, Reflecting Continuing Growth of VIVITROL® and ARISTADA® —

      —    New Drug Application Recently Submitted to FDA for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder —

      DUBLIN, Feb. 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the twelve months ended Dec. 31, 2017 and provided financial expectations for 2018. 

      Quarter Ended Dec. 31, 2017 Financial Highlights

      • Total revenues for the quarter were $275.4 million. This compared to $213.5 million for the same period in the prior year, representing an increase of 29%.
      • Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $9.8 million, or a basic and diluted GAAP loss per share of $0.06. This compared to GAAP net loss of $21.1 million, or a basic and diluted GAAP loss per share of $0.14 for the same period in the prior year.
      • Non-GAAP net income was $50.3 million, or a non-GAAP basic earnings per share of $0.33 and non-GAAP diluted earnings per share of $0.31, for the quarter. This compared to non-GAAP net income of $23.3 million, or a non-GAAP basic and diluted earnings per share of $0.15, for the same period in the prior year.

      Quarter Ended Dec. 31, 2017 Financial Results

      Revenues

      • Net sales of VIVITROL® were $75.6 million, compared to $62.1 million for the same period in the prior year, representing an increase of 22%.
      • Net sales of ARISTADA® were $28.3 million, compared to $17.3 million for the same period in the prior year, representing an increase of 64%.  
      • Manufacturing and royalty revenues from RISPERDAL CONSTA®, INVEGA SUSTENNA®/XEPLION® and INVEGA TRINZA®/TREVICTA® were $78.2 million, compared to $74.0 million for the same period in the prior year.
      • Manufacturing and royalty revenues from AMPYRA®/FAMPYRA®1 were $38.1 million, compared to $32.3 million for the same period in the prior year.
      • Revenues from the collaboration with Biogen for BIIB098 (formerly ALKS 8700) included $28.0 million of license revenue and $2.3 million of R&D reimbursement.

      Costs and Expenses

      • Operating expenses were $269.5 million, compared to $237.1 million for the same period in the prior year.
      • Income tax provision of $20.6 million included a $21.5 million tax charge related to the reduction in the value of our deferred tax assets due to the enactment of the Tax Cuts and Jobs Act of 2017. This compared to an income tax benefit of $3.2 million for the same period in the prior year.

      Calendar Year 2017 Financial Highlights

      • Total revenues increased 21% to $903.4 million in 2017, which included VIVITROL net sales of $269.3 million and ARISTADA net sales of $93.5 million. This compared to total revenues of $745.7 million for 2016, which included VIVITROL net sales of $209.0 million and ARISTADA net sales of $47.2 million. Please see the tables at the end of this press release for a detailed breakdown of the revenues from our key commercial products.
      • GAAP net loss was $157.9 million, or a basic and diluted GAAP loss per share of $1.03, for 2017. This compared to a GAAP net loss of $208.4 million, or a basic and diluted GAAP loss per share of $1.38, for 2016.
      • Non-GAAP net income was $27.8 million, or a non-GAAP basic earnings per share of $0.18 and non-GAAP diluted earnings per share of $0.17, for 2017. This compared to non-GAAP net loss of $10.3 million, or a non-GAAP basic and diluted loss per share of $0.07, for 2016.
      • At Dec. 31, 2017, Alkermes recorded cash, cash equivalents and total investments of $590.7 million, compared to $619.2 million at Dec. 31, 2016. At Dec. 31, 2017, the company's total debt outstanding was $281.4 million, compared to $283.7 million at Dec. 31, 2016.

      "Our financial results in 2017 were driven by the strong year-over-year growth of our proprietary products, VIVITROL and ARISTADA, our base royalty and manufacturing business and our strategic alliance with Biogen for BIIB098. We exited the year well positioned to execute on our key strategic initiatives in 2018," commented James Frates, Chief Financial Officer of Alkermes. "Looking ahead, 2018 will be a transformative year for Alkermes. Our financial expectations for 2018 reflect important investments that will drive future value as we advance our late-stage pipeline and prepare for the anticipated launch of ALKS 5461, with the planned expansion of our commercial organization midyear. We also expect solid growth for VIVITROL and ARISTADA, and remain committed to driving awareness and advancing the treatment paradigm for these important medicines."

      Recent Events:

      • ALKS 5461: In January 2018, Alkermes submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). ALKS 5461 was granted Fast Track status by the FDA in October 2013 for the adjunctive treatment of MDD in patients with an inadequate response to standard antidepressant therapies.
      • BIIB098: Biogen and Alkermes announced a license and collaboration agreement for the development and commercialization of BIIB098 for the treatment of relapsing forms of Multiple Sclerosis (MS). Under the terms of the agreement, Alkermes granted Biogen an exclusive, worldwide license to develop and commercialize BIIB098 and Biogen will pay Alkermes a mid-teens royalty on worldwide net sales of BIIB098. Biogen is responsible for all development and commercialization expenses, effective Jan. 1, 2018. Alkermes may also receive milestone payments for BIIB098 with a maximum aggregate value of $200 million upon certain clinical and regulatory achievements.
      • ARISTADA: A NDA was filed with the FDA for Aripiprazole Lauroxil NanoCrystal® Dispersion (ALNCD), a novel, investigational product designed for initiation onto ARISTADA. A target action date of June 30, 2018 was assigned to the ALNCD NDA under the Prescription Drug User Fee Act (PDUFA).
      • VIVITROL: Results from the National Institute on Drug Abuse (NIDA)-funded X:BOT study, comparing extended-release naltrexone (VIVITROL) and buprenorphine-naloxone, were published in The Lancet. Data from the study demonstrated that, once treatment was initiated, both medications were equally safe and effective in preventing relapse to opioid dependence.
      • ALKS 4230: Preclinical data on ALKS 4230 was presented at the Society of Immunotherapy of Cancer (SITC) Annual Meeting. The data showed that treatment with ALKS 4230 significantly delayed tumor growth and led to accumulation of tumor-killing T cells in the tumor microenvironment in individualized and humanized melanoma xenograft models of tumor immunology.

      "We are making significant progress in advancing our pipeline of late-stage CNS development candidates, highlighted by the recent submission of the ALKS 5461 NDA, the recently announced license and collaboration agreement with Biogen to develop and commercialize BIIB098, and as we near completion of enrollment in the six-month pivotal weight study for ALKS 3831," said Richard Pops, Chief Executive Officer of Alkermes. "Alkermes has worked for many years toward this moment. With a diversified CNS business and significant news flow expected across our pipeline of development candidates in 2018, we are focused on executing on our business strategy to bring these important potential new medicines to patients and creating value for our shareholders."

      2018 Expected Milestones

      The following outlines the company's expected milestones for 2018. The following statements are forward-looking, and actual results may differ materially. Please see "Note Regarding Forward-Looking Statements" at the end of this press release for risks that could cause results to differ materially from these forward-looking statements.

      • VIVITROL
        • Publication and presentation of detoxification protocols for induction onto VIVITROL from recent clinical trials (H1)
      • ARISTADA
        • ALNCD for initiation onto ARISTADA PDUFA target action date (June 30, 2018)
      • ALKS 5461
        • Assignment of PDUFA target action date, following NDA acceptance (Q2)
        • Potential Advisory Committee meeting and FDA action (H2)
      • ALKS 3831
        • ENLIGHTEN-2 six-month weight study enrollment completion (Q1)
        • Phase 1 human metabolic study data presentation (H1)
        • ENLIGHTEN-2 topline results (Fall)
      • BIIB098 (formerly ALKS 8700)
        • Potential receipt of $50 million payment following initial data from EVOLVE-MS-2 gastrointestinal head-to-head study (mid-2018)
        • Planned NDA submission for treatment of MS (H2)
      • ALKS 4230
        • Dose escalation data and dose expansion initiation (H2)
        • Planned submission of Investigational New Drug (IND) application for subcutaneous dosing phase 1 study (H2)

      Financial Expectations for 2018

      The following outlines the company's financial expectations for 2018, which include investments in commercial infrastructure in preparation for the expected launch of ALKS 5461 and in the company's pipeline of late-stage development candidates. The following statements are forward-looking, and actual results may differ materially. Please see "Note Regarding Forward-Looking Statements" at the end of this press release for risks that could cause results to differ materially from these forward-looking statements.

      • Revenues: The company expects total revenues to range from $975 million to $1.025 billion, driven by continuing growth of VIVITROL and ARISTADA. Included in this total revenue expectation, Alkermes expects VIVITROL net sales to range from $300 million to $330 million, and ARISTADA net sales to range from $140 million to $160 million.
      • Cost of Goods Manufactured and Sold: The company expects cost of goods manufactured and sold to range from $180 million to $190 million.
      • Research and Development (R&D) Expenses: The company expects R&D expenses to range from $415 million to $445 million.
      • Selling, General and Administrative (SG&A) Expenses: The company expects SG&A expenses to range from $555 million to $585 million. This increase reflects important planned investment in the expansion of our commercial organization in preparation for the anticipated launch of ALKS 5461.
      • Amortization of Intangible Assets: The company expects amortization of intangibles to be approximately $65 million.
      • Net Interest Expense: The company expects net interest expense to be approximately $10 million.
      • Income Tax Expense: The company expects income tax expense of up to $10 million.
      • GAAP Net Loss: The company expects GAAP net loss to range from $250 million to $280 million, or a basic and diluted loss per share of $1.61 to $1.81, based on a weighted average basic and diluted share count of approximately 155 million shares outstanding.
      • Non-GAAP Net Loss: The company expects non-GAAP net loss to range from $5 million to $35 million, or a non-GAAP basic and diluted loss per share of $0.03 to $0.23, based on a weighted average basic and diluted share count of approximately 155 million shares outstanding.
      • Capital Expenditures: The company expects capital expenditures to range from $80 million to $90 million.

      Conference Call

      Alkermes will host a conference call at 8:30 a.m. ET (1:30 p.m. GMT) on Wednesday, Feb. 14, 2018, to discuss these financial results and provide an update on the company. The conference call may be accessed by visiting Alkermes' website or by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. In addition, a replay of the conference call will be available from 11:00 a.m. ET (4:00 p.m. GMT) on Wednesday, Feb. 14, 2018, through 5:00 p.m. ET (10:00 p.m. GMT) on Wednesday, Feb. 21, 2018, and may be accessed by visiting Alkermes' website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.

      About Alkermes plc

      Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

      Non-GAAP Financial Measures

      This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.

      Non-GAAP net income (loss) adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; certain other one-time or non-cash items; and the income tax effect of these reconciling items.

      The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share should not be considered measures of our liquidity.

      A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.

      Note Regarding Forward-Looking Statements

      Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: future financial and operating performance, business plans or prospects; the likelihood of continued revenue growth from the company's commercial products, including the growth of VIVITROL and ARISTADA; the therapeutic and commercial value of the company's marketed and development products and patient access to such products; expectations concerning the timing and results of clinical development activities, including the timing of the phase 3 clinical trial enrollment completion and data readout for ALKS 3831, the timing of the presentation of ALKS 3831 phase 1 metabolic study data, the phase 1 data readout and timing of development activities for ALKS 4230, the timing of data from the EVOLVE-MS-2 head-to-head gastrointestinal study and the potential $50 million option payment by Biogen, the submission of the NDA for BIIB098, the acceptance of the NDA for ALKS 5461 by the FDA, and the timing of FDA review of the NDA for ALKS 5461; and expectations concerning the timing and results of commercial activities, including the expected launch of ALKS 5461. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so-called "Paragraph IV" litigation and other patent litigation, related to any of our products, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings, such as clinical trial designs, conduct and methodologies; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real-world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission ("SEC"), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.

      VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA® and NanoCrystal® are registered trademarks of Alkermes Pharma Ireland Limited; RISPERDAL CONSTA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson; AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc.

      1AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg is developed and marketed in the U.S. by Acorda Therapeutics, Inc. and outside the U.S. by Biogen Idec, under a licensing agreement with Acorda Therapeutics, as FAMPYRA® (prolonged-release fampridine tablets).

      (tables follow)

      Alkermes plc and Subsidiaries

      Selected Financial Information (Unaudited)













      Three Months


      Three Months



      Ended


      Ended

      Condensed Consolidated Statements of Operations - GAAP


      December 31,


      December 31,

      (In thousands, except per share data)


      2017


      2016

      Revenues:





        Manufacturing and royalty revenues


      $        138,700


      $        133,804

        Product sales, net


      103,941


      79,451

        License revenues


      28,000


      -

        Research and development revenues


      4,729


      259

          Total Revenues


      275,370


      213,514

      Expenses:





        Cost of goods manufactured and sold


      38,507


      34,957

        Research and development


      104,490


      89,626

        Selling, general and administrative


      110,896


      97,145

        Amortization of acquired intangible assets


      15,642


      15,323

          Total Expenses


      269,535


      237,051

      Operating Income (Loss)


      5,835


      (23,537)

      Other Income (Expense), net:





      Interest income


      1,362


      835

      Interest expense


      (3,192)


      (4,896)

      Change in the fair value of contingent consideration


      5,700


      4,800

      Other income (expense), net


      1,081


      (1,515)

          Total Other Income (Expense), net


      4,951


      (776)

      Income (Loss) Before Income Taxes


      10,786


      (24,313)

      Provision (Benefit) for Income Taxes


      20,575


      (3,172)

      Net Loss — GAAP


      $           (9,789)


      $         (21,141)






      Net (Loss) Earnings Per Share:





      GAAP net loss per share — basic and diluted


      $             (0.06)


      $             (0.14)

      Non-GAAP earnings per share — basic


      $              0.33


      $              0.15

      Non-GAAP earnings per share — diluted


      $              0.31


      $              0.15






      Weighted Average Number of Ordinary Shares Outstanding:





         Basic and diluted — GAAP


      153,865


      152,148

         Basic — Non-GAAP


      153,865


      152,148

         Diluted — Non-GAAP


      160,036


      159,212






      An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income is as follows:





      Net Loss — GAAP


      $           (9,789)


      $         (21,141)

         Adjustments:





      Share-based compensation expense


      20,581


      19,783

      Amortization expense


      15,642


      15,323

      Depreciation expense


      9,575


      9,325

      Income tax charge related to 2017 income tax reform (1)


      21,453


      -

      Non-cash net interest expense


      192


      194

      Loss on warrants and equity method investments


      64


      866

      Income tax effect related to reconciling items


      (1,726)


      1,636

      Change in the fair value of contingent consideration


      (5,700)


      (4,800)

      Loss on debt refinancing


      -


      2,075

      Non-GAAP Net Income


      $          50,292


      $          23,261













      Year Ended


      Year Ended

      Condensed Consolidated Statements of Operations - GAAP


      December 31,


      December 31,

      (In thousands, except per share data)


      2017


      2016

      Revenues:





        Manufacturing and royalty revenues


      $        505,308


      $        487,247

        Product sales, net


      362,834


      256,146

        License revenues


      28,000


      -

        Research and development revenues


      7,232


      2,301

          Total Revenues


      903,374


      745,694

      Expenses:





        Cost of goods manufactured and sold


      154,748


      132,122

        Research and development


      412,889


      387,148

        Selling, general and administrative


      421,578


      374,130

        Amortization of acquired intangible assets


      62,059


      60,959

          Total Expenses


      1,051,274


      954,359

      Operating Loss


      (147,900)


      (208,665)

      Other Income (Expense), net:





      Interest income


      4,649


      3,752

      Interest expense


      (12,008)


      (14,889)

      Change in the fair value of contingent consideration


      21,600


      7,900

      Other expense, net


      (9,615)


      (2,485)

        Total Other Income (Expense), net


      4,626


      (5,722)

      Loss Before Income Taxes


      (143,274)


      (214,387)

      Provision (Benefit) for Income Taxes


      14,671


      (5,943)

      Net Loss — GAAP


      $       (157,945)


      $       (208,444)






      Net (Loss) Earnings Per Share:





      GAAP net loss per share — basic and diluted


      $             (1.03)


      $             (1.38)

      Non-GAAP earnings (loss) per share — basic


      $              0.18


      $             (0.07)

      Non-GAAP earnings (loss) per share — diluted


      $              0.17


      $             (0.07)






      Weighted Average Number of Ordinary Shares Outstanding:





         Basic and diluted — GAAP


      153,415


      151,484

         Basic — Non-GAAP


      153,415


      151,484

         Diluted — Non-GAAP


      160,062


      151,484






      An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income (loss) is as follows:





      Net Loss — GAAP


      $       (157,945)


      $       (208,444)

         Adjustments:





      Share-based compensation expense


      83,917


      94,396

      Amortization expense


      62,059


      60,958

      Depreciation expense


      36,464


      33,298

      Income tax charge related to 2017 income tax reform (1)


      21,453


      -

      Other-than-temporary impairment of equity method investment


      10,471


      -

      Loss on warrants and equity method investments


      2,824


      2,130

      Non-cash net interest expense


      770


      888

      Income tax effect related to reconciling items


      (10,622)


      2,252

      Change in the fair value of contingent consideration


      (21,600)


      (7,900)

      Upfront license option payment to Reset Therapeutics, Inc. charged to R&D expense


      -


      10,000

      Loss on debt refinancing


      -


      2,075

      Non-GAAP Net Income (Loss)


      $          27,791


      $         (10,347)











      (1) - On December 22, 2017, the Tax Cuts and Jobs Act of 2017 was signed into law and has resulted in significant changes to the U.S. corporate income
      tax system including a federal corporate rate reduction from 35% to 21%.  The change in tax rate and tax law is accounted for in the period of enactment.
      Therefore, during the period ended December 31, 2017, we recorded a $21.5 million tax expense related to our current estimate of the provisions of the
      Tax Cuts and Jobs Act of 2017.






      Condensed Consolidated Balance Sheets


      December 31,


      December 31,

      (In thousands)


      2017


      2016

      Cash, cash equivalents and total investments


      $        590,716


      $        619,165

      Receivables


      233,590


      191,102

      Inventory


      93,275


      62,998

      Prepaid expenses and other current assets


      48,475


      39,344

      Property, plant and equipment, net


      284,736


      264,785

      Intangible assets, net and goodwill


      349,041


      411,100

      Other assets


      197,394


      137,929

      Total Assets


      $     1,797,227


      $     1,726,423

      Long-term debt — current portion


      $            3,000


      $            3,000

      Other current liabilities


      288,122


      208,993

      Long-term debt   


      278,436


      280,666

      Deferred revenue — long-term 


      5,657


      7,122

      Other long-term liabilities


      19,204


      17,161

      Total shareholders' equity


      1,202,808


      1,209,481

      Total Liabilities and Shareholders' Equity


      $     1,797,227


      $     1,726,423






      Ordinary shares outstanding (in thousands)


      154,009


      152,431






      This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's
      Annual Report on Form 10-K for the year ended December 31, 2017, which the company intends to file in February 2018.

      Alkermes plc and Subsidiaries

      Revenues for Calendar Year 2017 and 2016














      Three Months


      Three Months


      Three Months


      Three Months


      Year 



      Ended


      Ended


      Ended


      Ended


      Ended



      March 31,


      June 30,


      September 30,


      December 31,


      December 31,

      (In thousands)


      2017


      2017


      2017


      2017


      2017

      Revenues:











      PARTNERED LONG-ACTING ANTIPSYCHOTICS (1)


      $          60,003


      $          82,169


      $          79,443


      $          78,238


      $      299,853

      AMPYRA/FAMPYRA 


      29,219


      25,256


      24,478


      38,066


      117,019

      BYDUREON


      12,266


      11,635


      10,095


      11,700


      45,696

      VIVITROL


      58,456


      66,071


      69,178


      75,617


      269,322

      ARISTADA


      18,000


      22,685


      24,503


      28,324


      93,512

      Key Commercial Product Revenues


      177,944


      207,816


      207,697


      231,945


      825,402












      Legacy Product Revenues (2)


      13,191


      10,192


      8,661


      10,696


      42,740

      License Revenue(3)


      -


      -


      -


      28,000


      28,000

      Research and Development Revenues


      643


      833


      1,027


      4,729


      7,232

      Total Revenues


      $      191,778


      $      218,841


      $      217,385


      $      275,370


      $      903,374

























      Three Months


      Three Months


      Three Months


      Three Months


      Year 



      Ended


      Ended


      Ended


      Ended


      Ended



      March 31,


      June 30,


      September 30,


      December 31,


      December 31,

      (In thousands)


      2016


      2016


      2016


      2016


      2016

      Revenues:











      PARTNERED LONG-ACTING ANTIPSYCHOTICS (1)


      $          54,667


      $          69,578


      $          73,251


      $          73,967


      $      271,463

      AMPYRA/FAMPYRA 


      28,194


      40,848


      12,897


      32,254


      114,193

      BYDUREON


      10,533


      12,303


      11,554


      11,256


      45,646

      VIVITROL


      43,827


      47,242


      55,804


      62,109


      208,982

      ARISTADA


      5,547


      10,277


      13,998


      17,342


      47,164

      Key Commercial Product Revenues


      142,768


      180,248


      167,504


      196,928


      687,448












      Legacy Product Revenues (2)


      12,765


      14,305


      12,548


      16,327


      55,945

      Research and Development Revenues


      1,241


      612


      189


      259


      2,301

      Total Revenues


      $      156,774


      $      195,165


      $      180,241


      $      213,514


      $      745,694























      (1) - Includes RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA.











      (2) - Includes legacy product revenues, excluding product revenues sold as part of the Gainesville transaction.











      (3) - Includes the upfront payment allocated to the license sold to Biogen in connection with the BIIB098 collaboration.

       









      Alkermes plc and Subsidiaries

      2018 Guidance — GAAP to Non-GAAP Adjustments








      An itemized reconciliation between projected loss per share on a GAAP basis and projected loss per share







      on a non-GAAP basis is as follows:





















      (In millions, except per share data)


      Amount


      Shares


      Loss Per Share

      Projected Net Loss — GAAP


      $           (265.0)


      155


      $             (1.71)

         Adjustments:







      Non-cash net interest expense


      1.0





         Income tax effect related to reconciling items


      (3.5)





      Depreciation expense


      42.5





      Amortization expense


      65.0





      Share-based compensation expense


      140.0












      Projected Net Loss — Non-GAAP


      $             (20.0)


      155


      $             (0.13)















      Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.














      Alkermes Contacts:

      For Investors:

      Sandy Coombs    +1 781 609 6377


      Eva Stroynowski +1 781 609 6823

      For Media:     

      Jennifer Snyder   +1 781 609 6166

      Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.